Video

Combination neoadjuvant nivolumab/gemcitabine-cisplatin is efficacious in pathologically downstaging MIBC

Author(s):

Urology Times staff

“The complete response rates were 49%, which is quite impressive compared to historical controls,” says Shilpa Gupta, MD.

In this video, Shilpa Gupta, MD, discusses the background and findings of the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.

Related Videos
2 experts in this video
2 experts in this video
Timothy Lyon, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
1 expert is featured in this series.
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
1 expert is featured in this series.
Related Content
US FDA logo in white over a blue background. | Credit: US Food and Drug Administration
February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell
A recap of the FDA submissions and regulatory decisions in urology from January 2025.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
January 29th 2025

UTUC roundtable discussions highlight guidelines, patient cases

Urology Times staff
Two recent roundtable discussions focused on the challenges and evolving treatment strategies in upper tract urothelial carcinoma.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Anktiva under review in EU for BCG-unresponsive NMIBC with CIS
January 27th 2025

Anktiva under review in EU for BCG-unresponsive NMIBC with CIS

Hannah Clarke
If approved, the marketing authorization application would be valid in all 27 European Union member states as well as in Iceland, Liechtenstein, and Norway.
UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma
January 22nd 2025

UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma

Hannah Clarke
"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.
© 2025 MJH Life Sciences

All rights reserved.